Search

Author/Creator Cortes, Jorge E

6. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Issue 7 (July 2021)

Authors:
Lancet, Jeffrey E; Uy, Geoffrey L; Newell, Laura F; Lin, Tara L; Ritchie, Ellen K; Stuart, Robert K; Strickland, Stephen A; Hogge, Donna; Solomon, Scott R; Bixby, Dale L; Kolitz, Jonathan E; Schiller, Gary J; Wieduwilt, Matthew J; Ryan, Daniel H; Faderl, Stefan; Cortes, Jorge E
Journal:
Lancet
Issue:
Volume 8:Issue 7(2021)
Page Start:
e481
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Issue 9 (September 2019)

Authors:
Ravandi, Farhad; Assi, Rita; Daver, Naval; Benton, Christopher B; Kadia, Tapan; Thompson, Philip A; Borthakur, Gautam; Alvarado, Yesid; Jabbour, Elias J; Konopleva, Marina; Takahashi, Koichi; Kornblau, Steven; DiNardo, Courtney D; Estrov, Zeev; Flores, Wilmer; Basu, Sreyashi; Allison, James; Shar...
Journal:
Lancet
Issue:
Volume 6:Issue 9(2019)
Page Start:
e480
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗